# Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting

> **NCT01163604** · PHASE4 · COMPLETED · sponsor: **Jinling Hospital, China** · enrollment: 114 (actual)

## Conditions studied

- CVD

## Interventions

- **DRUG:** Argatroban
- **DRUG:** non-argatroban treated group

## Key facts

- **NCT ID:** NCT01163604
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2013-12
- **Final completion:** 2014-08
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2015-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163604, "Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01163604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*